SOURCE: Noble Financial Capital Markets
STAMFORD, CT--(Marketwire - Aug 23, 2012) - Noble Financial Capital Markets (Noble) will host BIOX, a life sciences investor exposition to be held at the University of Connecticut in Stamford, CT on September 24-25, 2012. In addition to world-renowned Dr. Phil Greenberg from the Fred Hutchinson Cancer Center and Dr. Charles Vacanti from Harvard Medical School, Dr. Mark Noble and Dr. Jeffrey Infante will participate at the two-day event.
Dr. Noble is Professor of Neurology, Genetics, and Neurobiology and Anatomy at University of Rochester School of Medicine and is Director of the University of Rochester Stem Cell and Regenerative Medicine Institute. He is one of the pioneers of stem cell research and directs research on multiple topics, including spinal cord injury, genetic diseases and cancer. He is an inventor on multiple patents, has consulted for multiple pharmaceutical and biotechnology companies and was a founding scientific advisory board member of Acorda Therapeutics, Inc., a biotechnology company focused on treatment of neurological disease. He is co-author of over 140 scientific publications. Dr. Noble will join corporate participants on the Cell Therapy & Regenerative Medicine panel at 11:45am on September 24.
Dr. Jeffrey Infante, the Executive Director of the Drug Development Program at the Sarah Cannon Research Institute, will lead the Targeted Oncology panel at 1:00pm on September 24. Dr. Infante received his undergraduate and medical degrees from the University of Florida. His residency was completed at Parkland Memorial Hospital, University of Texas Southwestern Medical Center and his fellowship in medical oncology was completed at Johns Hopkins University School of Medicine. He also earned a master of health science degree in epidemiology at Johns Hopkins University's Bloomberg School of Public Health. Dr. Infante has quickly emerged as a respected leader in the study of investigational agents and has authored numerous abstracts that have received international recognition in the oncology community.
In addition, the conference will feature a panel focused on Tissue Engineering & Biomaterials as well as a panel to discuss Advancements in Immunotherapy. In related news, the Cancer Research Institute (CRI) has joined the Alliance for Regenerative Medicine (ARM) as a supporter of Noble's BIOX Investor Exposition. For more than five-and-a-half decades, CRI has been a leading and sustaining force in immunotherapy and cancer immunotherapy research worldwide. Their goal, and the goal of several attending companies, is to discover and develop new, immune-based approaches to the treatment, control, and prevention of cancer.
Among attending life sciences companies are: Axogen (AXGN), Intergra Life Sciences (IART), InVivio (NVIV), MiMedx (MDXG), ISTO Technologies (pvt), Cytori (CYTX), Athersys (ATHX), Cytomedix (CMXI), Medistem (MEDS), Inovio (INO), PrimaBiomed (PBMD), Oncosec (ONCS), Provectus (PVCT), Galena (GALE), NewLink Genetics (NLNK), Argos (pvt), MethylGene (MYG.TO), Threshold (THLD), Synta (SNTA), Cornerstone Pharmaceuticals (pvt), Palatin (PTN), BioCryst (BCRX), Savient (SVNT). Noble expects fifteen additional companies to attend and participate.
For more information about CRI): http://www.cancerresearch.org/Default.aspx
For more information about ARM: http://www.alliancerm.org/event/biox-life-sciences-exposition
Conference website: http://www.nobleresearch.com/BioExposition.htm